prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Hamdullah Fitrat, Taliban's deputy spokesperson, said the Pakistani forces targeted a home in Paktia's Chamkani district, killing an elder and a child, while injuring others. The area was struck again 25 minutes after the first strike when residents had gathered to rescue people. 28 villagers died in the second strike while 158 more were wounded. Hospital footage showed infants and elderly victims on stretchers. A survivor directly refuted Pakistan's claims that the targets were terrorists. Additionally, six more civilians were killed in a Giyan district village in Paktika province. Pakistani electronic jammers also downed a drone in North Waziristan. On 29 June, insurgents killed a police constable in Bannu District, while four TTP militants were also killed in an operation in the district. An explosion and fire were reported in Kabul. Six border guards were killed, nine wounded and one abducted as Pakistani Taliban militants overrun a border post in Chitral District. On 30 June, an Afghan Refugees Camp was hit in a drone strike/shootdown in Pishin District and a school was hit by a drone strike in Kila Abdullah District, Pakistan Air Force also downed a drone in Quetta. Pakistan claimed to have shot down a total of four "rudimentary" drones from Afghanistan. Afghanistan claimed that its forces successfully hit an ISKP camp in Pishin District. Border post No. 2417 in Kurram District was targeted by sniper fire killing one Pakistani FC soldier. On 1 July, an Afghan drone was shot down by Pakistani forces in Khyber District.
=== Books === Boitano, Scott; Brooks, Heddwen L.; Barman, Susan M.; Barrett, Kim E. (2016). Ganong's Review of Medical Physiology. McGraw-Hill Education. ISBN 978-0-07-182510-8. Susan Standring, ed. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Cole, Laurence A.; Kramer, Peter R. (2016). Human Physiology, Biochemistry and Basic Medicine. Amsterdam: Academic Press. ISBN 978-0-12-803699-0.
=== Maximum-likelihood methods === The maximum-likelihood approach uses probability theory to complete all three steps simultaneously. It estimates critical parameters, including the divergence between sequences and the transition/transversion ratio, by deducing the most likely values to produce the input data.
Unk is sometimes used instead of Xaa, but is less standard. Ter or * (from termination) is used in notation for mutations in proteins when a stop codon occurs. It corresponds to no amino acid at all. In addition, many nonstandard amino acids have a specific code. For example, several peptide drugs, such as Bortezomib and MG132, are artificially synthesized and retain their protecting groups, which have specific codes. Bortezomib is Pyz–Phe–boroLeu, and MG132 is Z–Leu–Leu–Leu–al. To aid in the analysis of protein structure, photo-reactive amino acid analogs are available. These include photoleucine (pLeu) and photomethionine (pMet).
Sources: en.wikipedia.org
An – actinide Some actinides can exist in several oxide forms such as An2O3, AnO2, An2O5 and AnO3. For all actinides, oxides AnO3 are amphoteric and An2O3, AnO2 and An2O5 are basic, they easily react with water, forming bases:
== Effect == This receptor has an inhibitory function on most of the tissues in which it rests. In the brain, it slows metabolic activity by a combination of actions. At the neuron's synapse, it reduces synaptic vesicle release.
As early as 1718 letters from the Secretary at War were addressed from "The War Office". His department had several headquarters in London until it settled at Horse Guards in Whitehall during 1722. It remained there until 1858. Then, following the dissolution of the Board of Ordnance, the War Office moved into the Board's former offices in Cumberland House, Pall Mall. Over the ensuing years it expanded into adjacent properties on Pall Mall before it was relocated to purpose-built accommodation, in what is now known as the Old War Office Building, in 1906. Between 1906 and its abolition in 1964 the War Office was based in a large neo-Baroque building designed by William Young, completed during 1906, and located on Horse Guards Avenue at its junction with Whitehall in central London. The construction of the building required five years to complete, at a cost of more than 1.2 million pounds. The building is somewhat oddly shaped, forming a trapezoid to maximise the use of the irregularly shaped plot of land on which it was built: its four distinctive domes were designed as a decorative means of disguising the shape. It has around 1,100 rooms on seven floors. After 1964 the building continued to be used, under the name The Old War Office, by the Ministry of Defence. On 1 June 2007 the building, other than the steps that give access to it, was designated as a protected site for the purposes of Section 128 of the Serious Organised Crime and Police Act 2005. The effect was to make it a specific criminal offence for a person to trespass on the building.
As benzene can cause cancer, National Institute for Occupational Safety and Health recommends that all workers wear special breathing equipment when they are likely to be exposed to benzene at levels exceeding the recommended (8-hour) exposure limit of 0.1 ppm. According to Occupational Safety and Health Administration’s Supporting Statement for the Information Collection Request for the Benzene standard, an estimated 12,270 establishments are subject to the requirements of the standard.
=== Etymology === DuPont went through an extensive process to generate names for its new product. In 1940, John W. Eckelberry of DuPont stated that the letters "nyl" were arbitrary, and the "on" was copied from the suffixes of other fibers such as cotton and rayon. A later publication by DuPont (Context, vol. 7, no. 2, 1978) explained that the name was originally intended to be "No-Run" ("run" meaning "unravel") but was modified to avoid making such an unjustified claim. Since the products were not really run-proof, the vowels were swapped to produce "nuron", which was changed to "nilon" "to make it sound less like a nerve tonic". For clarity in pronunciation, the "i" was changed to "y". A persistent urban legend exists that the name is derived from "New York" and "London"; however, no organization in London was ever involved in the research and production of nylon.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.